Abstract:Objective: To identify novel biomarkers as an alternative diagnostic tool for limb girdle muscular dystrophy (LGMD). Background: LGMD encompasses a group of muscular dystrophies characterized by proximal muscles weakness, elevated CK levels and dystrophic findings on muscle biopsy. Heterozygous CAPN3 mutations are associated with autosomal dominant LGMD-4, while biallelic mutations can cause autosomal recessive LGMD-1. Diagnosis is currently often based on invasive methods requiring muscle biopsy or blood tests. In most cases Western blotting (WB) analysis from muscle biopsy is essential for a diagnosis, as muscle samples are currently the only known tissues to express the full-length CAPN3 isoform. Methods: We analyzed CAPN3 in a cohort including 60 LGMD patients. Selected patients underwent a complete neurological examination, electromyography, muscle biopsy, and skin biopsies for primary fibroblasts isolation. The amount of CAPN3 was evaluated by WB analysis in muscle and skin tissues. The total RNA isolated from muscle, fibroblast and urine was processed, and cDNA was used for qualitative analysis. The expression of CAPN3 was investigated by qRT-PCR. The CAPN3 3D structure has been visualized and analyzed using PyMOL. Results: Among our patients, seven different CAPN3 mutations were detected, of which two were novel. After sequencing CAPN3 transcripts from fibroblast and urine, we detected different CAPN3 isoforms surprisingly including the full-length transcript. We found comparable protein levels from fibroblasts and muscle tissue; in particular, patients harboring a novel CAPN3 mutation showed a 30% reduction in protein compared to controls from both tissues. Conclusions: Our findings showed for the first time the presence of the CAPN3 full-length transcript in urine and skin samples. Moreover, we demonstrated surprisingly comparable CAPN3 protein levels between muscle and skin samples, thus allowing us to hypothesize the use of skin biopsy and probably of urine samples as an alternative less invasive method to assess the amount of CAPN3 when molecular diagnosis turns out to be inconclusive.

Protein O-mannosyltransferase activities in lymphoblasts from patients with alpha-dystroglycanopathies

Phenotype and Genotype Study of Chinese POMT2-Related α-Dystroglycanopathy

Analysis of Phenotype, Enzyme Activity and Genotype of Chinese Patients with POMT1 Mutation.

Reduced proliferative activity of primary POMGnT1-null myoblasts in vitro

Novel Copy Number Variation of POMGNT1 Associated with Muscle-Eye-brain Disease Detected by Next-Generation Sequencing

Just Expect It: Compound Heterozygous Variants of POMT1 in a Consanguineous Family—The Role of Next Generation Sequencing in Neuromuscular Disorders

Genetic Variations and Clinical Spectrum of Dystroglycanopathy in a Large Cohort of Chinese Patients.

Molecular Interaction Between Fukutin and Pomgnt1 in the Glycosylation Pathway of Alpha-Dystroglycan

Novel mutations in B3GALNT2 gene causing α-dystroglycanopathy in Chinese patients

Glycosylation of α-dystroglycan: O-mannosylation influences the subsequent addition of GalNAc by UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases

Novel POMGnT1 Mutations Cause Muscle-Eye-brain Disease in Chinese Patients

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes

Gallus gallus orthologous to human alpha-dystroglycanopathies candidate genes: Gene expression and characterization during chicken embryogenesis

Novel Biomarkers for Limb Girdle Muscular Dystrophy (LGMD)

Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations

Clinical, Molecular Pathological and Genetic Analysis of a Chinese Family with Dystrophinopathy

From Past to Present: Pompe Disease, Pseudodeficiency Alleles, and Diagnostic Challenges

P.8.6 Genotype/phenotype analysis in Chinese laminin-α2 deficient congenital muscular dystrophy patients

Validation of a novel western blot assay to monitor patterns and levels of alpha dystroglycan in skeletal muscle of patients with limb girdle muscular dystrophies

Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease